Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EVO 756

Next Previous
Drug Profile

EVO 756

Alternative Names: EVO-756; MAS-related G-protein coupled receptor X2 inhibitor - Evommune; MRGPRX2 inhibitor - Evommune

Latest Information Update: 16 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dermira
  • Developer Evommune
  • Class Antiasthmatics; Antipruritics; Skin disorder therapies; Small molecules
  • Mechanism of Action MRGPRX2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Pruritus

Highest Development Phases

  • Phase II Atopic dermatitis; Chronic urticaria
  • Phase I Asthma
  • Preclinical Interstitial cystitis; Pruritus

Most Recent Events

  • 05 Mar 2026 Evommune plans a phase IIb trial in Migraine in mid-2026
  • 19 Sep 2025 Efficacy data from phase II clinical trials in Chronic-urticaria released by Evommune
  • 03 Sep 2025 Phase-II clinical trials in Atopic dermatitis in USA (PO) (NCT07150845)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top